The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , Yancopoulos , M.D.,

Antibody 52

Antibody Medicine Production Trials 52

XTalks

JANUARY 8, 2024

The FDA’s endorsement stems from results obtained from the company’s Phase III NefIgArd clinical trial. There, it specifically targets the mucosal B cells in the ileum to inhibit antibody formation. To begin treatment, prescribers must fill out the Tarpeyo Touchpoints Enrollment Form, which acts as the official prescription.

FDA Approval 64

FDA Approval Clinical Trials Clinical Trials Nurses 64

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., combined dose groups; 6.5%

Antibody 40

Antibody Trials Production Clinical Trials 40

XTalks

NOVEMBER 30, 2023

XTALKS WEBINAR: Unique Sourcing Solutions to Optimize Time and Budget in Clinical Trials Live and On-Demand: Friday, January 19, 2024, at 2pm EST (11am PST) Register for this free webinar to learn about innovative sourcing strategies for commercially available medications.

FDA Approval 101

FDA Approval Trials Clinical Trials Clinical Trials 101

Delveinsight

AUGUST 26, 2021

The company then utilizes the de-identified records to improve the design of clinical trials and quality of life measurements. Through the collaboration, the companies focus on connecting clinical trial data with specialty pharmacy information, natural history, registry data, and broad claims databases.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

The Pharma Data

DECEMBER 5, 2020

Potentially registrational Phase 2 portion of the trial has been initiated and is enrolling patients. NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma.

Antibody 40

Antibody Production Trials Medicine 40

XTalks

SEPTEMBER 22, 2023

XTALKS WEBINAR : How to Prepare and Analyze Your Lab Samples for Timely Clinical Decisions Live and On-Demand : Monday, November 6, 2023, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn about the importance of securing a reliable sample management flow as the foundation for downstream analysis in clinical trials.

Vaccination 59

Vaccination Vaccine FDA Approval Pharmacy 59

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. The results still require further validation, including experimental and clinical evaluation. The list also included melatonin.

Research 98

Research Hormones Protein Regulation 98

The Pharma Data

AUGUST 21, 2020

Roche and Regeneron join forces to increase global supply of an antibody cocktail for Covid-19. Roche and Regeneron have announced their partnership in the fight to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational anti-viral antibody cocktail, to people around the globe.

Vaccination 52

Vaccination Vaccine Manufacturing Contamination 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial. NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified.

Production 52

Production Antibody Manufacturing Trials 52

XTalks

AUGUST 30, 2022

The webinar also featured Kelsey Carter, MS, Clinical Trial Manager at Medpace who discussed the site, operational and regulatory challenges for neuroscience trials with direct CNS administration along with the strategies to mitigate these challenges. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

NOVEMBER 5, 2020

About the Trial The RECOVERY trial is conducted by the registered clinical trials units in the Nuffield Department of Population Health in partnership with the Nuffield Department of Medicine. The DMC letter is available here: [link]. Department of Health and Human Services under OT number: HHSO100201700020C.

Trials 52

Trials Production Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 8, 2021

They include proteins, monoclonal antibodies and vaccines that are considered to be “ highly similar ” to biological products that have already been approved by the FDA. What is a Biosimilar? Biosimilars are the “generic” drugs of the biopharma world. What is an Interchangeable Biological Product?

Production 78

Production Insulin Branding Generic Drugs 78

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Evaluation of its safety and efficacy is ongoing in multiple clinical trials.

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

The Pharma Data

NOVEMBER 18, 2021

Donations include updates from the DREAMM ( DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme and two cooperative studies that will demonstrate the eventuality of belantamab mafodotin, a first-in- classanti-BCMA (B- cell development antigen) remedy, in multiple myeloma. GSK pipeline trial.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Antibody 52

XTalks

JUNE 12, 2023

Medtronic’s proactive stance towards R&D is evident from the over 230 clinical trials it conducted and the more than 200 regulatory approvals it received in the US, Europe, Japan and China in the 2022 fiscal year. The company reported an investment of $2.7

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

The Pharma Data

JULY 29, 2021

Evaluation of baricitinib’s efficacy and safety as a treatment for COVID-19 is ongoing in clinical trials. Under the EUA, inpatient pharmacies in the U.S. In the COVID-19 clinical trials, adverse drug reactions in the safety population occurring in ? In the U.S., Adverse Reactions. Source link: [link].

HR 52

HR Licensing Licensing FDA Approval 52

The Pharma Data

NOVEMBER 18, 2020

Eli Lilly and Company’s antibody therapeutic will be distributed as part of the federal government’s Operation Warp Speed. . 18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. TAMPA, Fla., Have diabetes.

Antibody 40

Antibody Medicine Radiology Protein 40

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. Pfizer is actually working with Germany’s BioNTech on mRNA vaccines against the coronavirus, using strands of mRNA to generate protective antibodies. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

Pharmaceutical Technology

SEPTEMBER 10, 2008

was established in 1999 in the process of privatisation of the State Research Institute for Pharmacy and Biochemistry in the Czech Republic. Before the inception of this institute, the facility was oriented towards pre-clinical toxicology and breeding of the laboratory animals. Dr Ivana Surovà: Biotest s.r.o.

In-Vitro 130

In-Vitro Genotoxicity In-Vivo Clinical Research 130

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Evinacumab , an antibody to ANGPTL3.

Sales 52

Sales Production Manufacturing Antibody 52

The Pharma Data

OCTOBER 14, 2020

The treatment consists of three monoclonal antibodies of similar structure, atoltivimab, maftivimab and odesivimab, that bind to different, non-overlapping epitopes on Zaire ebolavirus glycoprotein. Inmazeb, previously called REGN-EB3, was created using Regeneron’s VelocImmune® platform and associated VelociSuite® technologies.

FDA Approval 52

FDA Approval Antibody Production Trials 52